Also known as: CJC
Molecular Weight
3367.97 Da
Half-Life
30 minutes (no DAC) / 5.8-8.1 days (with DAC)
Evidence Passport
Evidence strength, status, identity, route and safety are scored separately.
Human evidence
Human source linked; classification pending
A human source exists, but its strength and applicability have not completed review.
Development status
Investigational — phase 2
Investigational development is not the same as approval or product suitability.
Identity match
Named compound linked
Sources are linked to the named compound; formulation and product quality remain separate questions.
Route relevance
Study protocol recorded
At least one linked source records a studied protocol; it remains study context, not an instruction.
Safety record
6 documented flags
Documented flags are visible, but absence of a listed risk would not prove safety.
No major catalogue gap is flagged, but personal suitability and product quality remain separate.
2 app-verified sources linked · Version 2026-08-31
A long-acting GHRH analog that produces dose-dependent increases in mean plasma GH concentrations (2-10 fold for 6+ days) and IGF-I levels (1.5-3 fold for 9-11 days). After multiple doses, IGF-I remains elevated for up to 28 days. Synergistic with GHRP peptides.
These topics describe the catalogue's research index. They are not promised outcomes or personal recommendations.
CJC-1295 pharmacokinetics study (2006)
Produced sustained 2-10 fold elevation in GH and 1.5-3 fold IGF-1 increase
DOI: 10.1210/jc.2005-2664Explore more peptides in this category
View All Growth Hormone Peptides →Research Disclaimer: This information is compiled from published research and is provided for educational purposes only. Peptides discussed here are classified as research chemicals in most jurisdictions and are not FDA-approved for human use unless otherwise noted. Consult a qualified healthcare provider before starting any protocol.